The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis
نویسندگان
چکیده
BACKGROUND Many patients with relapsing-remitting multiple sclerosis (MS) treated with high-dose interferon-β (IFNβ) develop serum binding antibodies (BAb) and neutralizing antibodies (NAb). NAb reduces the biological activity of IFNβ, which contributes to clinical failure in these patients. We investigated whether access to antibody (Ab) test results would alter usual care of (IFNβ)-treated patients and whether BAb could predict NAb. METHODS This was a randomized, controlled, open-label, parallel-group, multicenter study in patients with multiple sclerosis. Subjects (n = 1358) were randomly assigned to Ab testing or usual care. BAb and NAb titres were measured using standard assays. Primary and secondary outcomes were the proportion of patients whose IFNβ therapy changed and the type of and reasons for therapy changes. RESULTS Therapy changes differed between the Ab testing and usual care arms (19.6% and 14.0%, respectively; p = 0 · 004). Results from Ab testing were more frequently reported as the reason for therapy change in the Ab testing arm than in the usual care arm (p < 0.0001). NAb and BAb positivity significantly increased the likelihood of therapy change and reduced IFNβ-associated adverse events. BAb titres were a significant predictor of NAb positivity (p = 0.0012). Initial BAb-positive and NAb-positive status in both study arms had a significant impact on the overall number of patients with a therapy change (p < 0.05). CONCLUSION Access to Ab test results impacted therapy management. BAb titres can predict NAb positivity in patients on high-dose IFNβ.
منابع مشابه
Inhibitory effect of the interferon-beta on the release of endothelial cell derived microparticles in patients with multiple sclerosis
Abstract Introduction: Increased levels of microparticles (MPs) have been reported in many autoimmune diseases such as multiple sclerosis (MS). In MS, endothelial cells release MPs from their membranes following the activation of lymphocytes and the production of inflammatory cytokines. The aim of this study was to investigate the inhibitory effect of interferon beta (INFβ) on the release of en...
متن کاملSide Effects of bb-Interferon: A Comparative Study Among Avonex, Betaseron and Rebif
The administration of b-interferon is a recognized treatment for multiple sclerosis. The frequency of side effects is an important factor in drug or product selection. In this study, the side effects of three available b<span style="font-family: TimesNew...
متن کاملInterferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis
Background: Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. Objective: To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Methods: Multiple sclerosis patients were randomized independently, in a double b...
متن کاملEffect of the Sera of Patients with Multiple Sclerosis on Apoptosis and Nitric Oxide Production of Endothelial Cells
Background & Aims: Multiple sclerosis (MS) is one of the chronic autoimmune diseases of the central nervous system with unknown etiology. The present study aimed to investigate the apoptosis and nitric oxide (NO) production of endothelial cells treated with serum of patients with MS and response to interferon beta (IFN- ) therapy. Methods: Human umbilical vein endothelial cells were treated wit...
متن کاملFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
متن کامل